MapLight Therapeutics (MPLT) Profit After Tax (2024 - 2026)
MapLight Therapeutics (MPLT) posted Profit After Tax of -$79.5 million for Q4 2025, down 170.37% sequentially from -$29.4 million in Q3 2025, and down 274.71% YoY from $45.5 million in Q4 2024.
Powered by 
Analysis
MapLight Therapeutics (MPLT) Profit After Tax (2024 - 2026) Analysis & Trends
MapLight Therapeutics has reported Profit After Tax for 2 years, with the latest figure at -$79.5 million in Q4 2025.
- Quarterly Profit After Tax fell 274.71% year-over-year to -$79.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$149.2 million (changed N/A YoY) and the FY2025 annual result came in at -$161.2 million, down 107.72% from the prior year.
- Profit After Tax eased to -$79.5 million in Q4 2025 per MPLT's latest filing, from -$29.4 million in the prior quarter.
- Over five years, Profit After Tax peaked at -$19.0 million in Q3 2024 and troughed at -$79.5 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | -16.62 Mn |
| 10 | MapLight Therapeutics | 629.68 Mn | 629.68 Mn | - | -60.25 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -60.25 Mn |
| Dec 31, 2025 | -79.82 Mn |
| Sep 30, 2025 | -29.42 Mn |
| Jun 30, 2025 | -29.88 Mn |
| Dec 31, 2024 | -21.23 Mn |
| Sep 30, 2024 | -19.02 Mn |